CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome

BACKGROUND: Li-Fraumeni syndrome (LFS) is characterized as an autosomal dominant cancer predisposition disorder caused by germline TP53 gene mutations. Both primary and therapy-related hematopoietic malignancies with LFS are associated with dismal outcomes with standard therapies and even allogenic...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Liting, Xu, Bin, Long, Xiaolu, Gu, Jia, Lou, Yaoyao, Wang, Di, Cao, Yang, Wang, Na, Li, Chunrui, Wang, Gaoxiang, Wang, Ying, Zhu, Li, Wang, Jin, An, Haiyun, Xiao, Min, Xiao, Yi, Zhou, Jianfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213909/
https://www.ncbi.nlm.nih.gov/pubmed/32345625
http://dx.doi.org/10.1136/jitc-2019-000364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213909/
https://www.ncbi.nlm.nih.gov/pubmed/32345625
http://dx.doi.org/10.1136/jitc-2019-000364

Ejemplares similares